Revenue
2022
2023
2024
MAIA Biotechnology, Inc. (MAIA)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | — |
| Research & development | $14.5M | $10.0M | $11.1M | $8.9M | $3.5M |
| Operating expenses | $24.3M | $17.0M | $20.2M | $16.2M | $7.8M |
| Operating income | −$24.3M | −$17.0M | −$20.2M | −$16.2M | −$7.8M |
| Net income | −$22.4M | −$23.3M | −$19.8M | −$15.8M | −$12.6M |
| Basic EPSper diluted share | -$0.70 | -$1.05 | -$1.49 | -$1.75 | -$2.37 |
| Diluted EPSper diluted share | -$0.70 | -$1.05 | -$1.49 | -$1.75 | -$2.37 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 | Vitoc VladChief Executive Officer | BuyCommon Stock | 72.7K | $1.39 | $101.1K | 976.1K |
| Jun 1, 2026Form 4 | Smith StanDirector | BuyCommon Stock · indirect | 75.0K | $1.34 | $100.5K | 1.52M |
| Jun 1, 2026Form 4 | Gryaznov SergeiChief Scientific Officer | BuyCommon Stock | 2.0K | $1.35 | $2.7K | 46.5K |
| Dec 22, 2025Form 4 | Smith StanDirector | BuyCommon Stock · indirect | 57.2K | $1.22 | $69.8K | 1.42M |
| Dec 22, 2025Form 4 | Smith StanDirector | BuyStock Options · derivative · indirect | 57.2K | $1.36 | $77.8K | 57.2K |